ZUG, Switzerland, and BERLIN, Feb. 26, 2018 /PRNewswire/ — The first drug designed to eliminate autoantibodies that are a major cause of heart failure and to treat heart failure symptoms was effective and well-tolerated in a Phase 1 clinical study, according to an oral presentation that…
